Yuri Deigin, Founder of Youthereum, speaking at Master Investor’s Investing in the Age of Longevity 2019 event.
Several studies have shown that OSKM induction (where O stands for Oct4) lowers epigenetic age gradually.
Having discovered this gradual property of epigenetic reprogramming, we can now be cautiously optimistic that we will manage to find a safe therapeutic window (such as marked by a yellow box in the graph) – that is, a period of safe epigenetic rollback when the methylation profile of a cell has been returned to a younger state but the cell has not lost its functional characteristics (for example, a skin cell would remain a skin cell rather than getting dedifferentiated into a pluripotent cell).
READ MORE: Youthereum Genetics
